Business
HeartBeam Reports First Quarter 2022 Financial Results
Company Remains on Track for FDA Submission of Emergency Department (ED) Myocardial Infarction (MI) Software Product in Q2 2022 & Telehealth Solution in Q4
About this update from Heartbeam, Inc.
[{"type":"text","content":"\nCompany Remains on Track for FDA Submission of Emergency Department (ED) Myocardial Infarction (MI) Software Product in Q2 2022 & Telehealth Solution in Q4 2022\n\nManagement to Host Webcast and Conference Call Today At 4:30 p.m. ET\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, has reported its financial and operational results for the first quarter ended March 31, 2022.\n\nFirst Quarter 2022 Operational Highlights\n\n\nEngaged Triple Ring Technologies to co-develop its telehealth complete solution 3D vector ECG collection device for remote heart attack, Myocardial Infarction (“MI”), monitoring.\n\n\nEngaged multiple partner health systems for ECG data sets to ensure FDA submission in Q2 2022.\n\n\nPartnered with Phoebe Putney Health System, signed a Business Associate Agreement and Clinical Trial Agreement to provide ECG data for this clinical trial designed to evaluate HeartBeam’s Emergency Department (“ED”) MI software product.\n\n\n\n\nSigned a partnership agreement with LIVMOR Inc., a digital health solutions company, to build a HeartBeam branded version of LIVMOR’s Halo+ FDA cleared platform for both use in the ED and for remote patient monitoring of patients with high risk for MI.\n\n\nEstablished a Scientific Advisory Board (“SAB”) to provide scientific guidance and insight to HeartBeam’s medical studies, research, and product pipelines. In conjunction, world-renowned cardiologist C. Michael Gibson, MD, MS, was appointed as Chairman of the SAB.\n\n\nManagement Commentary\n\n“We continue to operate from a position of strength, equipped with multiple strategic partnerships to advance product development, near-term milestones and cash runway into 2023,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “In collaboration with our LIVMOR partners our team continues to execute, readying our software for the planned submission to the FDA during the second quarter. Our partnership with Triple Ring Technologies is off to great start. The combined HeartBeam and Triple Ring team is making rapid progress in getting our 3D vector ECG collection device ready for FDA submission in Q4 of this year and readying it for production after FDA clearance,” commen...